Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinlarebant in Japanese Subjects with Stargardt Disease (Phase 1b PK/PD and Phase 2/3 Efficacy Study)
jRCT2031240209Phase 3Active, not recruiting
- Sponsor
- Belite Bio, Inc
- Start
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of tinlarebant in Fundus Flavimaculatus (FF) (3 arms), sponsored by Belite Bio, Inc. Primary endpoint: Annualized rate of change in aggregate area of atrophy. Started Jul 2024; status: active, not recruiting.
02
Drugs
tinlarebant
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on jRCT2031240209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240209.